Search Results for

MK-7684A-003

A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Continue Reading »

---

EA5182

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Anal  (1) Bladder/Urinary Tract Cancer  (7)    Adjuvant  (1)    Metastatic  (3)    Neoadjuvant  (1) Brain  (7)    Glioblastoma Multiforme (GBM)  (1)    Other Brain Tumors  (3) Breast  (14)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (21) Carcinoid Tumors  (2) Colorectal Cancer  (7)    Metastatic  (1)    Rectal Neoadjuvant  (1) Esophageal Cancer  (3) Gastric Cancer  (3) Head/Neck Cancer  (8) Leukemia  (1) Lung Cancer  (18)    Non-Small Cell Lung Cancer  (14)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (2)       Adjuvant Treatment for Resected NSCLC  (2)    Small Cell Lung Cancer  (3)       Extensive Stage SCLC  (1) MATCH Trial  (3) Melanoma  (2) Merkel Cell Carcinoma  (1) Misc. Gynecology  (3) Multiple Myeloma  (2) Ovarian  (2) Pancreatic  (7)    Metastatic Disease  (1) Prostate  (8) Renal Cell/Kidney Cancer  (3)    Locally Advanced/Metastatic  (1) Sarcoma  (1)